REG - Proteome Sciences - Change of Auditor

Proteome SciencesAnnouncement

04/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221004:nRSD6403Ba&default-theme=true

RNS Number : 6403B  Proteome Sciences PLC  04 October 2022

 

4 October 2022

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Change of Auditor

Proteome Sciences Plc ("Proteome Sciences", or "the Company") announces that
the Board has approved the appointment of Cooper Parry Group Limited (Cooper
Parry) as the Group's new external auditor, and that BDO LLP ("BDO") has
resigned as the Group's auditor.

Cooper Parry will conduct the audit of the Group's financial statements for
the financial period to 31 December 2022 and a proposal to re-appoint Cooper
Parry as auditors of the Group will be subject to the approval of
shareholders at the 2023 Annual General Meeting.

BDO has been the auditor for the Company since 2014 and we thank them for
their services over this time. BDO has confirmed to the Company that there are
no matters connected with their ceasing to hold office that need to be brought
to the attention of the members or creditors of the Company for the purposes
of section 519 of the Companies Act 2006.

- Ends -

For further information:

 Proteome Sciences plc

 Dr Mariola Soehngen, Chief Executive Officer  Tel: +44 (0)20 7043 2116

 Abdelghani Omari, Chief Financial Officer

 Dr Ian Pike, Chief Scientific Officer

 Richard Dennis, Chief Commercial Officer
 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale/ Jeremy
 Porter                           Tel: +44 (0)20 3328
 5656

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com) )

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant(®) and TMT(®)MS2 are unbiased methods for
identifying and contextualising new targets and defining mechanisms of
biological activity, while analysis using Super-Depletion and TMTcalibrator™
provides access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

 

The Company has its headquarters in Cobham, UK, with laboratory facilities in
Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFFFIFILLVIIF